Inhibition of autoimmune diabetes by Fas ligand

The paradox is solved

Sunshin Kim, Kyoung Ah Kim, Dae Youn Hwang, Tae Ho Lee, Nobuhiko Kayagaki, Hideo Yagita, Myung Shik Lee

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Previous reports that diabetogenic lymphocytes did not induce diabetes in nonobese diabetic (NOD)-lpr mice suggested the critical role of Fas-Fas ligand (FasL) interaction in pancreatic β cell apoptosis. However, recent works demonstrated that FasL is not an effector molecule in islet β cell death. We addressed why diabetes cannot be transferred to NOD-lpr mice despite the nonessential role of Fas in β cell apoptosis. Lymphocytes from NOD-lpr mice were constitutively expressing FasL. A decrease in the number of FasL+ lymphocytes by neonatal thymectomy facilitated the development of insulitis. Cotransfer of FasL+ lymphocytes from NOD-lpr mice completely abrogated diabetes after adoptive transfer of lymphocytes from diabetic NOD mice. The inhibition of diabetes by cotransferred lymphocytes was reversed by anti-FasL Ab, indicating that FasL on abnormal lymphocytes from NOD-lpr mice was responsible for the inhibition of diabetes transfer. Pretreatment of lymphocytes with soluble FasL (sFasL) also inhibited diabetes transfer, sFasL treatment decreased the number of CD4+CD45RB(low) cells and increased the number of propidium iodide-stained cells among CD4+CD45RB(low) cells, suggesting that sFasL induces apoptosis on CD4+CD45RB(low) 'memory' cells. These results resolve the paradox between previous findings and suggest a new role for FasL in the treatment of autoimmune disorders. Our data also suggest that sFasL is involved in the deletion of potentially hazardous peripheral 'memory' cells, contrary to previous reports that Fas on unmanipulated peripheral lymphocytes is nonfunctional.

Original languageEnglish
Pages (from-to)2931-2936
Number of pages6
JournalJournal of Immunology
Volume164
Issue number6
DOIs
Publication statusPublished - 2000 Mar 15

Fingerprint

Fas Ligand Protein
Type 1 Diabetes Mellitus
Inbred NOD Mouse
Lymphocytes
Apoptosis
Inhibition (Psychology)
Thymectomy
Adoptive Transfer
Propidium
Islets of Langerhans
Cell Death
Cell Count

All Science Journal Classification (ASJC) codes

  • Immunology

Cite this

Kim, S., Kim, K. A., Hwang, D. Y., Lee, T. H., Kayagaki, N., Yagita, H., & Lee, M. S. (2000). Inhibition of autoimmune diabetes by Fas ligand: The paradox is solved. Journal of Immunology, 164(6), 2931-2936. https://doi.org/10.4049/jimmunol.164.6.2931
Kim, Sunshin ; Kim, Kyoung Ah ; Hwang, Dae Youn ; Lee, Tae Ho ; Kayagaki, Nobuhiko ; Yagita, Hideo ; Lee, Myung Shik. / Inhibition of autoimmune diabetes by Fas ligand : The paradox is solved. In: Journal of Immunology. 2000 ; Vol. 164, No. 6. pp. 2931-2936.
@article{9639fe9126024de2983cef3d14bad3dd,
title = "Inhibition of autoimmune diabetes by Fas ligand: The paradox is solved",
abstract = "Previous reports that diabetogenic lymphocytes did not induce diabetes in nonobese diabetic (NOD)-lpr mice suggested the critical role of Fas-Fas ligand (FasL) interaction in pancreatic β cell apoptosis. However, recent works demonstrated that FasL is not an effector molecule in islet β cell death. We addressed why diabetes cannot be transferred to NOD-lpr mice despite the nonessential role of Fas in β cell apoptosis. Lymphocytes from NOD-lpr mice were constitutively expressing FasL. A decrease in the number of FasL+ lymphocytes by neonatal thymectomy facilitated the development of insulitis. Cotransfer of FasL+ lymphocytes from NOD-lpr mice completely abrogated diabetes after adoptive transfer of lymphocytes from diabetic NOD mice. The inhibition of diabetes by cotransferred lymphocytes was reversed by anti-FasL Ab, indicating that FasL on abnormal lymphocytes from NOD-lpr mice was responsible for the inhibition of diabetes transfer. Pretreatment of lymphocytes with soluble FasL (sFasL) also inhibited diabetes transfer, sFasL treatment decreased the number of CD4+CD45RB(low) cells and increased the number of propidium iodide-stained cells among CD4+CD45RB(low) cells, suggesting that sFasL induces apoptosis on CD4+CD45RB(low) 'memory' cells. These results resolve the paradox between previous findings and suggest a new role for FasL in the treatment of autoimmune disorders. Our data also suggest that sFasL is involved in the deletion of potentially hazardous peripheral 'memory' cells, contrary to previous reports that Fas on unmanipulated peripheral lymphocytes is nonfunctional.",
author = "Sunshin Kim and Kim, {Kyoung Ah} and Hwang, {Dae Youn} and Lee, {Tae Ho} and Nobuhiko Kayagaki and Hideo Yagita and Lee, {Myung Shik}",
year = "2000",
month = "3",
day = "15",
doi = "10.4049/jimmunol.164.6.2931",
language = "English",
volume = "164",
pages = "2931--2936",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "6",

}

Kim, S, Kim, KA, Hwang, DY, Lee, TH, Kayagaki, N, Yagita, H & Lee, MS 2000, 'Inhibition of autoimmune diabetes by Fas ligand: The paradox is solved', Journal of Immunology, vol. 164, no. 6, pp. 2931-2936. https://doi.org/10.4049/jimmunol.164.6.2931

Inhibition of autoimmune diabetes by Fas ligand : The paradox is solved. / Kim, Sunshin; Kim, Kyoung Ah; Hwang, Dae Youn; Lee, Tae Ho; Kayagaki, Nobuhiko; Yagita, Hideo; Lee, Myung Shik.

In: Journal of Immunology, Vol. 164, No. 6, 15.03.2000, p. 2931-2936.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Inhibition of autoimmune diabetes by Fas ligand

T2 - The paradox is solved

AU - Kim, Sunshin

AU - Kim, Kyoung Ah

AU - Hwang, Dae Youn

AU - Lee, Tae Ho

AU - Kayagaki, Nobuhiko

AU - Yagita, Hideo

AU - Lee, Myung Shik

PY - 2000/3/15

Y1 - 2000/3/15

N2 - Previous reports that diabetogenic lymphocytes did not induce diabetes in nonobese diabetic (NOD)-lpr mice suggested the critical role of Fas-Fas ligand (FasL) interaction in pancreatic β cell apoptosis. However, recent works demonstrated that FasL is not an effector molecule in islet β cell death. We addressed why diabetes cannot be transferred to NOD-lpr mice despite the nonessential role of Fas in β cell apoptosis. Lymphocytes from NOD-lpr mice were constitutively expressing FasL. A decrease in the number of FasL+ lymphocytes by neonatal thymectomy facilitated the development of insulitis. Cotransfer of FasL+ lymphocytes from NOD-lpr mice completely abrogated diabetes after adoptive transfer of lymphocytes from diabetic NOD mice. The inhibition of diabetes by cotransferred lymphocytes was reversed by anti-FasL Ab, indicating that FasL on abnormal lymphocytes from NOD-lpr mice was responsible for the inhibition of diabetes transfer. Pretreatment of lymphocytes with soluble FasL (sFasL) also inhibited diabetes transfer, sFasL treatment decreased the number of CD4+CD45RB(low) cells and increased the number of propidium iodide-stained cells among CD4+CD45RB(low) cells, suggesting that sFasL induces apoptosis on CD4+CD45RB(low) 'memory' cells. These results resolve the paradox between previous findings and suggest a new role for FasL in the treatment of autoimmune disorders. Our data also suggest that sFasL is involved in the deletion of potentially hazardous peripheral 'memory' cells, contrary to previous reports that Fas on unmanipulated peripheral lymphocytes is nonfunctional.

AB - Previous reports that diabetogenic lymphocytes did not induce diabetes in nonobese diabetic (NOD)-lpr mice suggested the critical role of Fas-Fas ligand (FasL) interaction in pancreatic β cell apoptosis. However, recent works demonstrated that FasL is not an effector molecule in islet β cell death. We addressed why diabetes cannot be transferred to NOD-lpr mice despite the nonessential role of Fas in β cell apoptosis. Lymphocytes from NOD-lpr mice were constitutively expressing FasL. A decrease in the number of FasL+ lymphocytes by neonatal thymectomy facilitated the development of insulitis. Cotransfer of FasL+ lymphocytes from NOD-lpr mice completely abrogated diabetes after adoptive transfer of lymphocytes from diabetic NOD mice. The inhibition of diabetes by cotransferred lymphocytes was reversed by anti-FasL Ab, indicating that FasL on abnormal lymphocytes from NOD-lpr mice was responsible for the inhibition of diabetes transfer. Pretreatment of lymphocytes with soluble FasL (sFasL) also inhibited diabetes transfer, sFasL treatment decreased the number of CD4+CD45RB(low) cells and increased the number of propidium iodide-stained cells among CD4+CD45RB(low) cells, suggesting that sFasL induces apoptosis on CD4+CD45RB(low) 'memory' cells. These results resolve the paradox between previous findings and suggest a new role for FasL in the treatment of autoimmune disorders. Our data also suggest that sFasL is involved in the deletion of potentially hazardous peripheral 'memory' cells, contrary to previous reports that Fas on unmanipulated peripheral lymphocytes is nonfunctional.

UR - http://www.scopus.com/inward/record.url?scp=0034653419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034653419&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.164.6.2931

DO - 10.4049/jimmunol.164.6.2931

M3 - Article

VL - 164

SP - 2931

EP - 2936

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 6

ER -